Pfizer receives EC approval for Hympavzi to treat haemophilia

Pfizer has received EC approval to expand the Hympavzi indication to treat haemophilia A or B with inhibitors in patients aged 12 years and over. The approval covers all 27 EU member states, Liechtenstein, Norway, and Iceland. The approval is based on Phase III BASIS trial data showing Hympavzi achieved a 93% reduction in bleeding rate. Credit: PaeGAG / Shutterstock.com. Pfizer has received the European Commission’s (EC) marketing authorisation for expanding the approved Hympavzi (marstacimab) indication to treat haemophilia A or B with inhibitors in patients aged 12 years and above. The approval covers adults and adolescents in the European…

Source: Pharmaceutical Technology